Minerva Urology and Nephrology最新文献

{"title":"YAU-RCC Insights from UROonco25 and EMUC25: renal cell carcinoma in a multidisciplinary era.","authors":"Savio D Pandolfo, Riccardo Campi, Daniele Amparore","doi":"10.23736/S2724-6051.26.07063-1","DOIUrl":"https://doi.org/10.23736/S2724-6051.26.07063-1","url":null,"abstract":"","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":"78 3","pages":"303-307"},"PeriodicalIF":5.1,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148431464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Authors' reply to: \"Robotic retrohepatic inferior vena cava thrombectomy using the caudate lobectomy technique: indications and initial outcomes\".","authors":"Jialong Song, Cheng Peng, Qingbo Huang","doi":"10.23736/S2724-6051.26.07067-9","DOIUrl":"https://doi.org/10.23736/S2724-6051.26.07067-9","url":null,"abstract":"","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":"78 3","pages":"444-445"},"PeriodicalIF":5.1,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148431497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First report of safety and outcomes of radiofrequency ablation of renal tumors using a new automated energy delivery-controlled system.","authors":"Giuseppe Ferrillo, Eleonora Baldassarre, Tiziano Sirugo, Silvio Romano, Ezio Lanza, Dario Poretti, Alberto Saita, Riccardo Levi, Giovanni Lughezzani, Nicolò M Buffi, Paolo Casale, Marco Francone, Vittorio Pedicini","doi":"10.23736/S2724-6051.26.06732-7","DOIUrl":"https://doi.org/10.23736/S2724-6051.26.06732-7","url":null,"abstract":"<p><strong>Background: </strong>The aim of this study was to retrospectively evaluate technical efficacy and safety of radiofrequency ablation (RFA) of renal tumors using a novel RF system.</p><p><strong>Methods: </strong>Eighty-two patients with 85 renal tumors (renal cell, papillary and chromophobe carcinomas, oncocytomas and lymphoma) considered unsuitable for surgery by the local Multidisciplinary Board were enrolled for RFA. Tumor location was exophytic in 49.4% of patients, endophytic in 36.5% and central in 14.1%, and tumor size was below 3 cm in 68/85 (80%) cases and between 3.1 and 4.3 cm in the remaining 17 (20%). A new high-power RF system with a maximum power of 370W, a pulsing algorithm for automated control of energy deposition and internally-cooled electrode tip up to 5 cm long was used. Technical success and technique efficacy (also related to size and location of tumors), and safety were evaluated. The follow-up period ranged from 12 to 26 months.</p><p><strong>Results: </strong>The ablation time was much shorter than with conventional RF systems, ranging between 12 and 15 minutes. At the immediate post-procedural assessment, the technical success was 100%. At the first follow-up evaluation, at two months, primary technique efficacy was achieved in 80/85 (94.1%) cases, without significant differences according to tumor location and size. The 5 partially ablated tumors were successfully retreated and the secondary technique efficacy at 12 months was 100%. Considering only the subgroup of the 45 patients with cyto-histologically proven RCC, the primary technique efficacy was 88.9% (40/45 cases) and the secondary was 100%. Significant complications, CIRSE grade 3, occurred in 3/90 (3.3%) procedures, but only one required treatment (transarterial embolization), while minor complications, all spontaneously remitting, occurred in 27/90 procedures. RFA performed with this new technology proved to be fast, effective and safe, and was associated with shorter procedure times and very few major complications, thus reducing or bridging the gap with MWA and CA.</p><p><strong>Conclusions: </strong>RFA performed with this new modality resulted safe and effective and it is associated with short procedural times. The automatic energy-delivery controlled system might overcome limitations due to long procedural times and heat-sink effect in RFA.</p>","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":"78 3","pages":"363-372"},"PeriodicalIF":5.1,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148430792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preliminary feasibility of SHURUI single-port robot-assisted radical cystectomy with exploratory comparison to a contemporaneous da Vinci Xi single-port cohort.","authors":"Qingyi Zhu, Jun Wang, Yong Wei, Wei Liu, Luming Shen, Christian D Fankhauser, Min Gu","doi":"10.23736/S2724-6051.26.06898-9","DOIUrl":"https://doi.org/10.23736/S2724-6051.26.06898-9","url":null,"abstract":"<p><strong>Background: </strong>Single-port robot-assisted surgery represents the latest advancement in minimally invasive urological oncology. The SHURUI single-port (SP) surgical robot system recently received approval as a second SP system and as alternative to the Da Vinci platform. We report the first comparison of the two systems in radical cystectomy patients.</p><p><strong>Methods: </strong>We conducted a retrospective comparative study at a tertiary referral center comparing operative and oncological outcomes in consecutive patients with bladder cancer who underwent single incision radical cystectomy using either the SHURUI SP-SR system or the Da Vinci Xi system.</p><p><strong>Results: </strong>We treated eleven patients using the SHURUI SP-SR system and 24 patients using the Da Vinci Xi system. We successfully completed all procedures without conversion. Baseline characteristics were generally similar between groups, and short-term perioperative, postoperative recovery, complication, and pathological outcomes were broadly comparable. No unexpected safety concerns were identified. Study limitations include small sample size, single-surgeon experience, retrospective design, and short follow-up.</p><p><strong>Conclusions: </strong>We demonstrated that in the first experiences SHURUI SP achieves comparable perioperative safety and efficacy to Da Vinci Xi for single incision radical cystectomy. Our findings support SHURUI as a potential alternative, potentially expanding robotic surgery access.</p>","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":"78 3","pages":"383-388"},"PeriodicalIF":5.1,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148431024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences in efficacy and safety between HIF-PHIS and ESA/placebo in a sample of hemodialysis patients: a systematic review and meta-analysis.","authors":"Valeria Cernaro, Veronica Maressa, Guido Gembillo, Giulio Geraci, Chiara Casucelli, Cristina Rossano, Domenico Santoro, Vincenzo Calabrese","doi":"10.23736/S2724-6051.25.06243-3","DOIUrl":"10.23736/S2724-6051.25.06243-3","url":null,"abstract":"<p><strong>Background: </strong>Treatment of anemia is one of the main goals of supportive care in patients on hemodialysis. In this context, the use of therapy with hypoxia inducible factor inhibitors (HIF-PHI) represents a further promising resource. The main objective is to evaluate the difference in hemoglobin levels after treatment with HIF-PHI compared to placebo/ESA.</p><p><strong>Methods: </strong>We performed a systematic search in PubMed, CINAHL, EMBASE, and Register of Controlled Trials (CENTRAL), looking for randomized controlled trials (RCTs). Eligible studies considered hemodialysis patients older than 18 years with the diagnosis of anemia treated with HIF-PHIs. Protocol was previously published on PROSPERO (CRD42024589848).</p><p><strong>Results: </strong>Among a total of 126 references, 32 citations were selected by screening of titles and abstracts, for full-text evaluation, and 14 articles referring were included in the review after the screening for full-text articles. Data on hemoglobin differences were reported by all studies and the pooled analysis involving 3890 patients (2267 in the experimental group and 1623 in the control group), network metanalysis did not show significant differences in Delta Hemoglobin among any HIF-PHIs types and ESA/placebo. Similarly, no significant differences were found comparing HIF-PHIs to ESA Splitting (11 studies, N.=3611). However, a significant difference was found comparing HIF-PHIs to Placebo (MD=1.48, 95%CI: 1.15/1.81, P<0.001). The experimental and control groups differed for gastrointestinal adverse events, whereas there were no differences for any other adverse events.</p><p><strong>Conclusions: </strong>The similar efficiency and safety between HIF-PHIs and ESA care could modify the usual clinical treatment of anemia in hemodialysis patients, and allow personalized therapy.</p>","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":" ","pages":"343-351"},"PeriodicalIF":5.1,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145034341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of refractory idiopathic overactive bladder with incobotulinumtoxinA and vibe delivery system (XAVIER): pilot study.","authors":"Omri Schwarztuch Gildor, Avner Geva, Avi Eftel, Frederico Branco, Luis Xambre, Roger R Dmochowski, Michael Vainrib","doi":"10.23736/S2724-6051.26.06822-9","DOIUrl":"10.23736/S2724-6051.26.06822-9","url":null,"abstract":"<p><strong>Background: </strong>Intradetrusor botulinum neurotoxin type A (BoNT/A) with onabotulinumtoxinA (onabotA), is an established treatment for overactive bladder (OAB). This study aims to evaluate the safety, usability, and initial efficacy of ViXe - a combination of incobotulinumtoxinA with the needle-free, ultrasound-assisted intravesical Vibe delivery system - in women with OAB.</p><p><strong>Methods: </strong>Parallel, exploratory, multicenter, randomized, double-masked, placebo- and sham-controlled. Women (18-80 years) with idiopathic OAB were randomized 1:1 to ViXe or placebo. Primary endpoints: 12-week safety and patient satisfaction. Secondary endpoints: initial efficacy measured by bladder diaries and validated questionnaires.</p><p><strong>Results: </strong>Eighty-two screened, 48 were randomized (ViXe 25; placebo 23); 47 completed. Safety: Treatment-emergent adverse events occurred in 44.0% ViXe vs. 39.1% placebo patients; fewer events were reported in the ViXe group (13 vs. 17); all mild-moderate; no serious events. Treatment-related adverse events were fewer with ViXe (8.0%) than with placebo (21.7%). Patient experience favored ViXe on several comfort domains; willingness to continue was higher (73.7% vs. 28.6%). Urinary incontinence decreased by 58% compared to 35% at week 6 and 59% compared to 45% at week 12 (ViXe vs. placebo); Overactive bladder questionnaires showed improvement in both groups, but it was not statistically significant. Satisfaction favored ViXe, with 63.16% patients satisfied, versus 57.14% dissatisfied in the placebo group.</p><p><strong>Conclusions: </strong>ViXe is safe and well-tolerated, with only mild to moderate AEs. The needle-free, office-amenable workflow and handling advantages of incobotulinumtoxinA support feasibility and patient acceptability. These data collectively justify a larger, adequately powered Phase 2b/3 trial to determine clinical efficacy and assess durability.</p>","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147976348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of an integrated multidimensional nomogram for predicting stone-free status after retrograde intrarenal surgery: a machine learning-based approach.","authors":"Zufa Zhang, Long Li, Zheyang Meng, Wenkai Li, Bin Hou, Kedi Niu, Long Lv, Zuyi Chen, Danni He, Hongxuan Song, Weibing Sun, Feng Tian, Sheng Guan, Fengze Jiang, Sixiong Jiang","doi":"10.23736/S2724-6051.26.06628-0","DOIUrl":"https://doi.org/10.23736/S2724-6051.26.06628-0","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to develop and validate a novel preoperative nomogram to predict stone-free status (SFS) in patients undergoing retrograde intrarenal surgery (RIRS) for kidney stones.</p><p><strong>Methods: </strong>A total of 312 patients who underwent RIRS were retrospectively analyzed. Robust predictors were selected using the intersection of the least absolute shrinkage and selection operator (LASSO) regression and the Boruta algorithm. Eight machine-learning algorithms were trained and compared. The optimal model was determined based on the receiver operating characteristic curve (ROC), Decision-curve analysis (DCA), and other evaluation indicators, with 5-fold cross-validation performed for internal validation. The best-performing algorithm (LogisticTEST) was further interpreted using Shapley Additive Explanations (SHAP) and visualized through a nomogram. Internal validation was performed with 1,000 bootstrap resamples.</p><p><strong>Results: </strong>Seven key predictors were identified, including stone volume, mean stone density, calyx pelvic height, inferior pole stone, laser mode, Operative Team Proficiency Score, and Number of stones. Among all models, LogisticTEST demonstrated the best discrimination (AUC=0.965) and the greatest clinical net benefit on DCA. SHAP analysis reveals that laser mode is the most critical predictor influencing stone-free status, and the predictive capability of SFS for each patient can be well clinically explained through SHAP. The logistic-based nomogram exhibited strong calibration and interpretability, providing an intuitive clinical decision-support tool.</p><p><strong>Conclusions: </strong>A machine learning-driven logistic model incorporating laser mode and team experience accurately predicted postoperative SFR following RIRS. Future multi-centre external validation and prospective studies are required to validate our findings.</p>","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147977387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"External validation of the prostatic inflammation nomogram to predict prostatic inflammation in men with lower urinary tract symptoms.","authors":"Riccardo Lombardo, Emanuele Pillitteri, Marta Santioni, Carolina Cerullo, Antonio Cicione, Giorgia Tema, Antonio Franco, Alessandro Guercio, Nicola Ghezzo, Antonio Nacchia, Andrea Vecchione, Gian L Rampioni Vinciguerra, Cristian Fiori, Enrico Bollito, Martina Mandaletti, Antonio L Pastore, Yazan Al Salhi, Andrea Fuschi, Stavros Gravas, Celeste Manfredi, Davide Arcaniolo, Francesca Pagliuca, Michele Marchioni, Luigi Schips, Michael Samarinas, Andrea Tubaro, Cosimo DE Nunzio","doi":"10.23736/S2724-6051.25.06720-5","DOIUrl":"https://doi.org/10.23736/S2724-6051.25.06720-5","url":null,"abstract":"<p><strong>Background: </strong>Recently a nomogram has been developed to predict prostatic inflammation. Aim of our study is to validate the prostatic inflammation nomogram (PIN) for predicting the presence of prostatic inflammation in men with lower urinary tract symptoms (LUTS).</p><p><strong>Methods: </strong>A consecutive series of men (≥40 years) with benign prostatic hyperplasia (BPH)/LUTS scheduled for prostatic surgery or transrectal ultrasound-guided (TRUS) prostate biopsy were enrolled. The presence of inflammation in the prostatic tissue samples, assessed according to the Irani score, was determined. Inflammation was classified using the Irani score into two categories: 0-2 (no/minimal inflammation) and 3-6 (moderate/severe inflammation). The discrimination, calibration, and net benefit of the nomogram were evaluated.</p><p><strong>Results: </strong>A total of 429 patients (mean age 70 years) were recruited. Overall, 257/429 (60%) presented with prostatic inflammation. On multivariable binary logistic regression analysis diabetes mellitus (OR=2.28; P=0.006), higher storage International Prostate Symptom Score score (OR=1.17; P<0.001), a prostate volume greater than 50 mL (OR=2.14; P<0.001), a positive urine dipstick test for leukocytes (OR=4.37; P<0.001) and a history of previous urinary tract infections (OR=2.34; P<0.001) were predictors of inflammation. Receiver operating characteristic analysis showed the nomogram with an AUC of 0.76 (95% CI: 0.72-0.81). Calibration was fair, and the nomogram demonstrated clinical net benefit within a probability range of 30% to 85%.</p><p><strong>Conclusions: </strong>The PIN nomogram showed good predictive ability and net benefit. Its use may help individualize treatment for LUTS by identifying candidates for therapies targeting prostatic inflammation.</p>","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147943778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Office-based transperineal laser ablation in patients with large prostates (≥80 mL): real-world evidence of safety and efficacy from a prospective single center cohort.","authors":"Paolo Polverino, Luisa Moscardi, Mattia Lo Re, Corso Caneschi, Giulio R Resta, Beatrice Giustozzi, Francesca Conte, Salvatore Granata, Alessio Pecoraro, Riccardo Campi, Vincenzo Li Marzi, Agostino Tuccio, Sergio Serni, Francesco Sessa","doi":"10.23736/S2724-6051.26.06687-5","DOIUrl":"https://doi.org/10.23736/S2724-6051.26.06687-5","url":null,"abstract":"<p><p>Transperineal laser ablation (TPLA) is emerging as a minimally invasive, office-based treatment for benign prostatic obstruction, but there is still a lack of evidence regarding its results in large prostates. The aim of this work was to evaluate safety, feasibility, and functional outcomes of TPLA in patients with prostate volume ≥80 mL. Data from consecutive patients undergoing TPLA April 2021 and February 2025 were prospectively collected in a dedicated institutional database, queried to select those patients with a prostate volume ≥80 mL who underwent TPLA. All procedures were performed under local anesthesia in an outpatient setting. A total of 234 patients underwent TPLA during the study period. Of these, 43 met the inclusion criteria for prostate volume and were included in the analysis. At the time of the surgery, 5 patients (12%) had an indwelling catheter and 36 (84%) were on medical therapy for BPO. Preoperative median prostate volume was 96 mL. At a median 12-month follow-up, uroflowmetry and symptom scores improved significantly, with preserved sexual and ejaculatory function. No major complications occurred. The catheter was successfully removed in 3 out of 5 (60%) patients with an indwelling catheter before TPLA. A total of four patients (9%) required additional surgical intervention during follow-up time. Our findings suggest that TPLA may be a safe and effective alternative to conventional surgery even in large prostates, warranting further validation through larger and comparative studies.</p>","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147595993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of hyaluronic acid in the treatment of Peyronie's disease in the light of the European Urology Guidelines: the real-world experience.","authors":"Alessandro Zucchi, Giuseppe Maiolino, Matteo Pacini, Giada Macrì, Juan I Martínez Salamanca, Giuseppe Dachille, Antonio Vitarelli, Vincenzo Ficarra, Antonio L Pastore, Luca Lepri, Carlo Porrozzi, Riccardo Bartoletti, Fabrizio Scroppo","doi":"10.23736/S2724-6051.25.06662-5","DOIUrl":"10.23736/S2724-6051.25.06662-5","url":null,"abstract":"<p><strong>Background: </strong>Peyronie's disease (PD) is a progressive fibrotic disorder of the tunica albuginea that impairs penile anatomy, sexual function, and quality of life. With no approved pharmacological treatments in Europe after the withdrawal of collagenase Clostridium histolyticum (CCH), intralesional hyaluronic acid (HA) has emerged as a potential option. This study aims to assess the clinical effectiveness of HA in PD, focusing on patient-reported outcomes via the Peyronie's Disease Questionnaire (PDQ).</p><p><strong>Methods: </strong>This prospective observational study included patients treated with weekly intralesional HA injections for 8 weeks, combined with penile modeling and daily tadalafil. Inclusion required a penile curvature >30° and at least one episode of penetrative intercourse within the past 3 months. Penile curvature, IIEF-5, and PDQ scores were assessed at baseline and after 3 months.</p><p><strong>Results: </strong>Sixty-six patients were included. Total PDQ scores improved from 61.5 (50.0-67.0) to 40.0 (26.8-49.0; P<0.001), with a mean reduction of -19.9±9.7. Specifically, all three domains of the PDQ questionnaire (Penile Pain, Penile Deformity, and Symptom Bother) showed a significant improvement (P<0.001). No adverse events were recorded.</p><p><strong>Conclusions: </strong>Intralesional HA injections are safe and effective in improving patient's reported symptoms and subsequently quality of life in PD patients. This therapy may represent a valuable alternative in real-world clinical practice, especially in Europe where other pharmacological options are lacking.</p>","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":" ","pages":"275-282"},"PeriodicalIF":4.2,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145783617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}